Northpointe Capital LLC cut its stake in Genocea Biosciences Inc. (NASDAQ:GNCA) by 21.1% during the second quarter, Holdings Channel reports. The institutional investor owned 756,017 shares of the company’s stock after selling 201,606 shares during the period. Northpointe Capital LLC’s holdings in Genocea Biosciences were worth $3,100,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Franklin Resources Inc. increased its position in shares of Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock valued at $22,342,000 after buying an additional 779,400 shares in the last quarter. State Street Corp increased its position in shares of Genocea Biosciences by 11.9% in the first quarter. State Street Corp now owns 291,020 shares of the company’s stock valued at $2,256,000 after buying an additional 30,920 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the company’s stock valued at $1,060,000 after buying an additional 1,743 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Genocea Biosciences during the first quarter valued at approximately $662,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Genocea Biosciences during the first quarter valued at approximately $565,000. 56.49% of the stock is currently owned by institutional investors.
Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) traded down 0.90% during mid-day trading on Wednesday, hitting $4.42. The stock had a trading volume of 316,311 shares. The stock’s market capitalization is $125.24 million. Genocea Biosciences Inc. has a 52 week low of $2.56 and a 52 week high of $8.20. The stock has a 50 day moving average of $5.35 and a 200-day moving average of $4.73.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. On average, equities research analysts predict that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current year.
Several research analysts have commented on GNCA shares. FBR & Co reaffirmed a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Tuesday, July 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a research report on Thursday, September 29th. Finally, Piper Jaffray Cos. dropped their price target on Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, September 29th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Genocea Biosciences presently has a consensus rating of “Buy” and an average price target of $16.96.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences Inc. (NASDAQ:GNCA).
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.